Infinium Pharmachem Ltd

Infinium Pharmachem Ltd

₹ 229 -1.29%
28 Mar - close price
About

Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]

Key Points

Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis

  • Market Cap 319 Cr.
  • Current Price 229
  • High / Low 316 / 70.8
  • Stock P/E 33.6
  • Book Value 38.8
  • Dividend Yield 0.00 %
  • ROCE 35.9 %
  • ROE 53.2 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 54.6%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Working capital days have increased from 60.9 days to 88.6 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Sep 2023
79 61
71 51
Operating Profit 9 10
OPM % 11% 17%
1 0
Interest 1 1
Depreciation 0 1
Profit before tax 8 8
Tax % 22% 24%
6 6
EPS in Rs 5.40 4.46
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
39 71 99 114
36 66 89 98
Operating Profit 2 5 10 16
OPM % 6% 7% 10% 14%
1 1 1 1
Interest 1 1 2 3
Depreciation 1 1 1 1
Profit before tax 1 4 9 13
Tax % 30% 28% 23% 24%
1 3 7 10
EPS in Rs 4.65 13.60 30.55 9.30
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 43%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 123%
TTM: 55%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 55%
Last Year: 53%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 1 1 1 5 14
Reserves 3 6 12 17 40
9 11 23 29 0
9 17 23 19 48
Total Liabilities 22 34 59 71 102
4 5 4 19 19
CWIP 0 4 8 0 0
Investments 0 0 0 0 0
18 26 46 52 83
Total Assets 22 34 59 71 102

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
3 7 12 9
-1 -5 -7 -5
-1 -1 -2 -3
Net Cash Flow 1 1 3 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 75 59 57 49
Inventory Days 84 62 78 89
Days Payable 82 79 56 31
Cash Conversion Cycle 76 43 78 108
Working Capital Days 76 36 58 89
ROCE % 32% 38% 36%

Shareholding Pattern

Numbers in percentages

Sep 2023
73.05%
26.95%
No. of Shareholders 646

Documents